No association of Brain-derived neurotrophic factor with striatal dopamine transporter availability in healthy subjects

Abstract

Objective Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays a key role in brain plasticity, synaptic function, neuronal survival, learning, and memory formation. We aimed to investigate the association of BDNF with dopamine transporter (DAT) availabilities measured by positron emission tomography (PET) in healthy subjects.

Methods Thirty-five healthy, male subjects without brain injury, neuropsychological disorders were included in this study. The emission data were acquired over 90 mins with 50 frames after injection of 18F-FP-CIT using PET. Binding potentials (BP_NDs) of ventral striatum (VST), caudate nucleus, putamen were measured with the simplified reference tissue method. The serum BDNF level (pg/mL) was measured through enzyme-linked immunosorbent assay method.

Results Thirty-five healthy males with a mean age of 24.4 ± 2.7 years were included in this study. Multiple regression was done to investigate the association between striatal BPNDs from VST, caudate nucleus, putamen and serum BDNF after adjusting for age. None of striatal BPNDs from VST (p=0.8450), caudate nucleus (p=0.4783), and putamen (p=0.7994) were associated with serum BDNF.

Conclusion Striatal DAT availabilities measured from PET were not associated with the serum BDNF in healthy subjects.

Zusammenfassung

Ziel Der Wachstumsfaktor BDNF (Brain-derived neurotrophic factor) ist ein Neurotrophin, das eine Schlüsselrolle bei der Plastizität des Gehirns, der synaptischen Funktion, dem neuronalen Überleben, dem Lernen und der Gedächtnisbildung spielt. Unser Ziel war es, mittels Positronen-Emissions-Tomografie (PET) die Assoziation von BDNF und dem Vorhandensein von Dopamin-Transportern (DAT) bei gesunden Probanden zu untersuchen.

Methoden 35 gesunde, männliche Probanden ohne Hirnverletzungen und neuropsychologische Störungen wurden in diese Studie aufgenommen. Die Emissionsdaten wurden über 90min mit 50 Frames nach Injektion von 18F-FP-CIT mittels PET erfasst. Die Bindungspotenziale (BPNDs) von ventralem Striatum (VST), Nucleus caudatus und Putamen wurden mit der vereinfachten Referenzgewebemethode gemessen. Der Serum-BDNF-Spiegel (pg/mL) wurde mittels ELISA (Enzyme-linked-Immunosorbent-Assay) bestimmt.

Ergebnisse 35 gesunde Männer mit einem Durchschnittsalter von 24,4±2,7 Jahren wurden in diese Studie aufgenommen. Mittels multipler Regression wurde die Assoziation zwischen striatalen BPNDs aus VST, Nucleus caudatus, Putamen und Serum-BDNF nach Altersbereinigung untersucht. Keine der striatalen BPNDs von VST (p=0,8450), Nucleus caudatus (p=0,4783) und Putamen (p=0,7994) waren mit Serum-BDNF assoziiert.

Schlussfolgerung Das mittels PET gemessene Vorhandensein von striatalen DAT war bei gesunden Probanden nicht mit Serum-BDNF assoziiert.

Schlüsselwörter

Dopamin-Membran-Transportproteine - Wachstumsfaktor BDNF - Positronen-Emissions-Tomografie

Keywords

Dopamine Plasma Membrane Transport Proteins - Brain-derived neurotrophic factor - Positron emission tomography

Publikationsverlauf

Eingereicht: 18. Februar 2021

Angenommen nach Revision: 31. Mai 2021

Artikel online veröffentlicht:
13. Juli 2021

• References

• 1 Edelmann E, Lessmann V, Brigadski T. Pre- and postsynaptic twists in BDNF secretion and action in synaptic plasticity. Neuropharmacology 2014; 76(C): 610-627
• 2 Panja D, Bramham CR. BDNF mechanisms in late LTP formation: A synthesis and breakdown. Neuropharmacology 2014; 76(C): 664-676
• 3 Hernandez-Vara J, Saez-Francas N, Lorenzo-Bosquet C. et al. BDNF levels and nigrostriatal degeneration in "drug naive" Parkinson's disease patients. An "in vivo" study using I-123-FP-CIT SPECT. Parkinsonism Relat Disord 2020; 78: 31-35
• 4 Hwang KS, Lazaris AS, Eastman JA. et al. Plasma BDNF levels associate with Pittsburgh compound B binding in the brain. Alzheimers Dement (Amst) 2015; 1: 187-193
• 5 Lima Giacobbo B, Doorduin J, Klein HC. et al. Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation. Mol Neurobiol 2019; 56: 3295-3312
• 6 Salehi Z, Mashayekhi F. Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease. J Clin Neurosci 2009; 16: 90-93
• 7 Ventriglia M, Zanardini R, Bonomini C. et al. Serum brain-derived neurotrophic factor levels in different neurological diseases. Biomed Res Int 2013; 2013: 901082
• 8 Vaughan RA, Foster JD. Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacol Sci 2013; 34: 489-496
• 9 Park E. A new era of clinical dopamine transporter imaging using 123I-FP-CIT. J Nucl Med Technol 2012; 40: 222-228
• 10 Ziebell M, Khalid U, Klein AB. et al. Striatal dopamine transporter binding correlates with serum BDNF levels in patients with striatal dopaminergic neurodegeneration. Neurobiol Aging 2012; 33: 428.e421-425
• 11 Frim DM, Uhler TA, Galpern WR. et al. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci U S A 1994; 91: 5104-5108
• 12 Pak K, Seo S, Kim K. et al. Striatal dopamine transporter changes after glucose loading in humans.. Diabetes Obes Metab 2020; 22: 116-122
• 13 Piccinni A, Marazziti D, Del Debbio A. et al. Diurnal variation of plasma brain-derived neurotrophic factor (BDNF) in humans: an analysis of sex differences. Chronobiol Int 2008; 25: 819-826
• 14 Ferris MJ, Espana RA, Locke JL. et al. Dopamine transporters govern diurnal variation in extracellular dopamine tone. Proc Natl Acad Sci U S A 2014; 111: E2751-2759
• 15 Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4: 153-158
• 16 Zipursky RB, Meyer JH, Verhoeff NP. PET and SPECT imaging in psychiatric disorders. Can J Psychiatry 2007; 52: 146-157
• 17 Hinderberger P, Rullmann M, Drabe M. et al. The effect of serum BDNF levels on central serotonin transporter availability in obese versus non-obese adults: A [(11)C]DASB positron emission tomography study. Neuropharmacology 2016; 110: 530-536